Zions Bancorporation, National Association’s Allogene Therapeutics ALLO Stock Holding History

Zions Bancorporation, National Association’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$686	Buy	+330	New	+$725	﹤0.01%	1496

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Zions Bancorporation, National Association's ALLO Position: Q2 2026 in Review

Zions Bancorporation, National Association opened a new position in Allogene Therapeutics (ALLO) in Q2 2026: 330 shares worth $686. The stake represents ﹤0.01% of the portfolio and ranks #1496 among its holdings.

209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

Zions Bancorporation, National Association held 330 shares of Allogene Therapeutics worth $686 as of Q2 2026.
Allogene Therapeutics was a new Zions Bancorporation, National Association position in Q2 2026.
Allogene Therapeutics made up ﹤0.01% of Zions Bancorporation, National Association's portfolio in Q2 2026, its #1496 holding.
209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Zions Bancorporation, National Association's 13F filing for Q2 2026, filed 31 Jul 2026.